Portal hypertension is a key determinant of the risk for liver-related events in non-alcoholic fatty liver disease

Affiliations

¹ Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria; Vienna Hepatic Hemodynamic Lab, Medical University of Vienna, Vienna, Austria.
² Department of Gastroenterology and Hepatology, Antwerp University Hospital, Edegem, Belgium; Laboratory of Experimental Medicine and Pediatrics (LEMP), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
³ Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria; Vienna Hepatic Hemodynamic Lab, Medical University of Vienna, Vienna, Austria; Christian Doppler Laboratory for Portal Hypertension and Liver Fibrosis, Medical University of Vienna, Vienna, Austria. Electronic address: thomas.reiberger@meduniwien.ac.at.

Comment

Rafael Paternostro et al. J Hepatol. 2023 Mar.

. 2023 Mar;78(3):e102-e104.

doi: 10.1016/j.jhep.2022.08.031. Epub 2022 Sep 5.

¹ Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria; Vienna Hepatic Hemodynamic Lab, Medical University of Vienna, Vienna, Austria.
² Department of Gastroenterology and Hepatology, Antwerp University Hospital, Edegem, Belgium; Laboratory of Experimental Medicine and Pediatrics (LEMP), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
³ Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria; Vienna Hepatic Hemodynamic Lab, Medical University of Vienna, Vienna, Austria; Christian Doppler Laboratory for Portal Hypertension and Liver Fibrosis, Medical University of Vienna, Vienna, Austria. Electronic address: thomas.reiberger@meduniwien.ac.at.

No abstract available

Keywords: NAFLD; NASH; advanced chronic liver disease; cirrhosis; hepatic decompensation; portal hypertension.

Comment on

Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design.
Allen AM, Therneau TM, Ahmed OT, Gidener T, Mara KC, Larson JJ, Canning RE, Benson JT, Kamath PS. Allen AM, et al. J Hepatol. 2022 Nov;77(5):1237-1245. doi: 10.1016/j.jhep.2022.07.004. Epub 2022 Jul 16. J Hepatol. 2022. PMID: 35843374 Free PMC article.